Analgesics Market: Industry Trends and Forecast 2024-2032
The Analgesics Market Size was valued at USD 45.68 billion in 2022 and is projected to reach USD 66.19 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2023 to 2030.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/1290
Analgesics, commonly known as painkillers, are drugs used to relieve pain without causing loss of consciousness. The rising incidence of chronic diseases, increasing geriatric population, and growing awareness regarding pain management have been key drivers of the global analgesics market. With the continuous advancements in pharmaceuticals and biotechnology, the market is witnessing a steady rise in demand for both opioid and non-opioid analgesics.
Market Description
Analgesics play a critical role in the healthcare system, offering relief from acute and chronic pain. Their use spans across postoperative care, cancer-related pain, arthritis, and other musculoskeletal disorders. The market is being positively influenced by the increasing adoption of self-medication and over-the-counter (OTC) availability of various analgesic drugs. Furthermore, rising healthcare expenditure, a growing aging population susceptible to pain-related conditions, and expanding access to medical care globally are accelerating market growth.
Regional Analysis
- North America holds the largest market share, driven by a strong healthcare infrastructure, high awareness levels, and a growing number of pain-related conditions such as arthritis and cancer.
- Europe follows closely, with increased adoption of pain management therapies and government initiatives to improve healthcare access.
- Asia-Pacific is expected to witness the fastest growth during the forecast period due to increasing healthcare spending, large population base, and rising demand for advanced treatment options in emerging economies like India and China.
- Latin America, the Middle East, and Africa are gradually emerging as potential markets due to growing healthcare investments and improving medical infrastructure.
Market Segmentation
- By Type
- Opioids
- Non-Opioids
- By Route of Administration
- Oral
- Topical
- Transdermal
- Intravenous
- Others
- By Application
- Neuropathic Pain
- Migraine
- Arthritis
- Cancer Pain
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Key Players in the Analgesics Market and Their Related Products
- Bayer AG
- Aspirin (acetylsalicylic acid)
- Aleve (naproxen)
- Endo International plc
- Percocet (acetaminophen and oxycodone)
- Opana (oxymorphone)
- Assertio Holdings, Inc.
- Lodine (etodolac)
- Zipsor (diclofenac potassium)
- Janssen Global Services, LLC
- Duragesic (fentanyl transdermal patch)
- Nucynta (tapentadol)
- GSK plc
- Panadol (acetaminophen)
- Voltaren (diclofenac)
- AbbVie Inc.
- Norco (hydrocodone and acetaminophen)
- Vicodin (hydrocodone and acetaminophen)
- Novartis AG
- Emgality (galcanezumab) – for migraines
- Ibrance (palbociclib) – for pain associated with cancer treatment
- Viatris Inc.
- Over-the-counter analgesics, including ibuprofen and acetaminophen products
- Teva Pharmaceutical Industries Ltd.
- Fentanyl (generic) – for severe pain
- Hydrocodone (generic)
- F. Hoffmann-La Roche Ltd.
- Actemra (tocilizumab) – for pain in rheumatoid arthritis
- RoActemra (tocilizumab)
- Sanofi
- Ambien (zolpidem) – for pain-related insomnia
- Paracetamol (acetaminophen) products
- Pfizer Inc.
- Celebrex (celecoxib)
- Advil (ibuprofen)
- Merck & Co., Inc.
- Mobic (meloxicam)
- Januvia (sitagliptin) – indirectly associated with pain from diabetes complications
- AstraZeneca
- Nexium (esomeprazole) – pain relief related to acid reflux
- Symbicort (budesonide/formoterol) – indirectly related to pain from asthma
- Johnson & Johnson Services, Inc.
- Tylenol (acetaminophen)
- Duragesic (fentanyl transdermal patch)
- Hikma Pharmaceuticals PLC
- Ibuprofen (generic)
- Oxycodone (generic)
- Dr. Reddy’s Laboratories Ltd.
- Ibuprofen (generic)
- Diclofenac (generic)
- Lupin
- Paracetamol (acetaminophen) products
- Ibuprofen (generic)
- Fresenius Kabi AG
- Injectable morphine
- Other injectable painkillers
- Aurobindo Pharma
- Hydrocodone (generic)
- Ibuprofen (generic)
- Cipla
- Diclofenac (generic)
- Paracetamol (acetaminophen)
- Bausch Health Companies Inc.
- Voltaren (diclofenac)
- Qutenza (capsaicin patch) – for pain management
- Amneal Pharmaceuticals LLC
- Ibuprofen (generic)
- Oxycodone (generic)
- Apotex Inc.
- Acetaminophen (generic)
- Ibuprofen (generic)
- Lilly
- Emgality (galcanezumab) – for migraines and chronic pain
Recent Development
Key Highlights
- Rising prevalence of chronic pain and post-surgical pain cases fueling demand.
- Increasing usage of OTC analgesics for minor to moderate pain.
- Technological innovation and R&D efforts expanding product portfolios.
- Regulatory changes driving safer usage of opioid-based medications.
- Growing geriatric population boosting market expansion.
Future Scope
As the demand for effective and safe pain relief continues to grow, the analgesics market is expected to witness significant advancements in drug development, including targeted delivery systems and non-addictive alternatives to opioids. Biopharmaceutical innovations, especially in personalized medicine and non-opioid pain management therapies, will further shape the future landscape. Additionally, ongoing digitalization in healthcare, including e-pharmacy growth and remote consultations, will enhance the accessibility of analgesics to wider populations across the globe.
Conclusion
The analgesics market is on a robust growth trajectory, backed by an increasing global demand for pain management, a rise in chronic diseases, and constant innovation in pharmaceuticals. As regulatory frameworks evolve and healthcare systems become more patient-centric, the market is poised to witness sustainable expansion over the coming years.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
Comments
0 comment